TargetMol

Ondansetron hydrochloride dihydrate

Product Code:
 
TAR-T1478
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1478-1mL1 mL * 10 mM (in DMSO)£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1478-25mg25mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1478-50mg50mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1478-100mg100mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1478-200mg200mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1478-1g1g£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ondansetron hydrochloride is a competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
CAS:
103639-04-9
Formula:
C18H24ClN3O3
Molecular Weight:
365.86
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9971
SMILES:
O.O.Cl.Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C
Target:
5-HT Receptor

References

1. Ye JH, et al. CNS Drug Rev. 2001, 7(2):199-213. 2. Weissenburger J, et al. Fundam Clin Pharmacol. 2009, 23(6):719-26. 3. Sardi I, et al. Cancer Lett. 2014, 353(2):242-7.